Longeveron (LGVN) Share-based Compensation (2020 - 2026)
Longeveron (LGVN) recorded quarterly Share-based Compensation of $379000.0 in Q1 2026, up 0.8% quarter-over-quarter from $376000.0 in Q4 2025, and up 11.47% on a YoY basis from $340000.0 in Q1 2025.
Longeveron (LGVN) Share-based Compensation (2020 - 2026) Analysis & Trends
Longeveron's Share-based Compensation history runs 7 years deep, the most recent figure standing at $379000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 11.47% year-over-year to $379000.0; the TTM figure through Mar 2026 stood at $1.7 million (down 28.97% YoY), while the FY2025 annual figure was $1.7 million, down 27.96% from the prior year.
- Share-based Compensation was $379000.0 for Q1 2026 at Longeveron, up from $376000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.4 million in Q3 2024 to a low of $200000.0 in Q2 2024.
- Historically, Share-based Compensation has averaged $510647.1 across 5 years, with a median of $421000.0 in 2023.
- Biggest YoY gain for Share-based Compensation was 312.61% in 2022; the steepest drop was 79.97% in 2022.
- A 5-year view of Share-based Compensation shows it stood at $476000.0 in 2022, then fell by 13.24% to $413000.0 in 2023, then fell by 5.57% to $390000.0 in 2024, then fell by 3.59% to $376000.0 in 2025, then increased by 0.8% to $379000.0 in 2026.
- The last three Share-based Compensation figures came in at $379000.0 (Q1 2026), $376000.0 (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 379,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 379,000.00 |
| Mar 31, 2026 | 379,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 340,000.00 |
| Mar 31, 2025 | 340,000.00 |
| Dec 31, 2024 | 390,000.00 |
| Dec 31, 2024 | 390,000.00 |
| Sep 30, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 295,000.00 |
| Mar 31, 2024 | 295,000.00 |
| Dec 31, 2023 | 413,000.00 |
| Dec 31, 2023 | 413,000.00 |